Top Takeaways from the National Lipid Association 2019 Scientific Sessions- What you should share with your healthcare team

Released On
December 2, 2019

Expires On
December 2, 2020

Media Type
Internet

Completion Time
60 minutes

Specialty
Endocrinology, Primary Care

Topic(s)
Lipid Treatment

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by National Lipid Association.

 

Supported by an educational grant from Amgen and Kowa Pharmaceuticals America, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Physician Assistants - NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
  • Pharmacists — maximum of 1.0 contact hours. (1CEUs).
  • Nurses — maximum of 1.0 contact hours, includes 0.8 pharmacotherapy contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the needs of lipid specialist, internists, endocrinologists, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and those with an interest in lipid management.

Program Overview

Did you miss the National Lipid Association’s 2019 Scientific Sessions? View this recorded webinar to hear Yale School of Medicine Associate Professor Dr. Nihar Desai cover the top takeaways you should share with your team on refining ASCVD risk assessment for individualized primary prevention, landmark cardiovascular outcomes trials, and choosing the appropriate therapeutic interventions for your diabetic patients at risk for ASCVD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review the 2018 ACC/AHA/NLA Guideline on the Management of Blood Cholesterol for the role of coronary artery calcium (CAC) scoring as a risk marker for atherosclerotic cardiovascular disease (ASCVD)
  • Discuss the implications of lipid treatment outcomes trials for the clinical management of patients with dyslipidemia.
  • Compare therapeutic options for the treatment of diabetes.

Faculty

Alan S. Brown, MD, FNLA

Director, Division of Cardiology
Advocate Heart Institute
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Chicago, IL

Nihar R. Desai, MD, MPH

Assistant Professor of Medicine (Cardiology)
Yale School of Medicine
Haven, CT

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

The National Lipid Association designates this internet enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™ Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

Pharmacist Accreditation Statement

Universal Activity Number – JA0007192-0000-19-053-H01-P (Knowledge)
This Activity has been approved for 1.00 contact hour(s) (.1CEUs) of the Accreditation Council for Pharmacy Education.

Nursing Continuing Education

This continuing education activity offered the maximum number of hours awarded for this CE activity is 1.0 contact hours.

This continuing education activity offered 0.8 pharmacotherapy contact hours.

Disclosures of Conflicts of Interest

Brown, Alan

  • Advisory Board: Akcea, Amgen, Kowa Pharmaceuticals America, Inc., Regeneron, sanofi-aventis
  • Speaker: Akcea, Amgen, Kowa Pharmaceuticals America, Inc., Regeneron, sanofi-aventis

Desai, Nihar

  • Contracted Research: Amgen, Boehringer Ingelheim, Cytokinetics, Novartis, and Relypsa
  • Consultant: Amgen, Boehringer Ingelheim, Cytokinetics, Novartis, and Relypsa

Staff/Reviewer Disclosures

  • NLA: NLA staff has nothing to disclose.
  • Elkins, Casey, DNP: Speaker: Regeneron/ Sanofi

Disclosure of Unlabeled Use and Investigational Products

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.

Permissions

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Criteria for Success

Statements of credit will be awarded based on the participant’s participation in the activity and post-assessment with a score of 75% or greater and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.